Company / Capital Returned to Shareholders
Bio-Rad Laboratories Capital Returned to Shareholders History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$295.5M
FY2025
5-year range
$50.0M / $428.7M
FY2021-FY2025
Trend
+45.1%
vs FY2024
Sector context
#46 of 108
Health Care
What the data says
At $296M, Bio-Rad Laboratories's capital returned to shareholders ranks #46 of 108 in the Health Care sector. Declined from $429M to $296M over the past 2 years.
Based on SEC 10-K filings.
$296M in FY2025 with a 5-year CAGR of +43.3%.
Declined from $429M to $296M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- +11.1%
- 5-Year CAGR
- +43.3%
- 10-Year CAGR
- -
Sector benchmark
#46 of 108 in Health CareTop 43% of 108This company $295.5M Sector average $744.4M
▼
-60.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +43.3%, indicating consistent growth.
- In FY2025, capital returned to shareholders increased 45.1% year-over-year.
- Ranks #46 out of 108 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2023.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $295.5M | +45.1% |
| FY2024 | $203.6M | -52.5% |
| FY2023 | $428.7M | +98.7% |
| FY2022 | $215.7M | +331.4% |
| FY2021 | $50.0M | +2.2% |
| FY2020 | $48.9M | +74.7% |
| FY2019 | $28.0M | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026